EC Approves Lunsumio, Roche’s Bispecific Antibody for Follicular Lymphoma

Roche has received approval from the European Commission for Lunsumio (mosunetuzumab), the first CD20xCD3 T-cell engaging bispecific antibody for treating follicular lymphoma.